We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+1.62%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$825M
AUM Growth
-$13.1M
Cap. Flow
-$4.93M
Cap. Flow %
-0.6%
Top 10 Hldgs %
40.43%
Holding
69
New
13
Increased
13
Reduced
19
Closed
21

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$35.8M
2
UHS icon
Universal Health Services
UHS
+$31.9M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$28.3M
4
AGN
Allergan Inc
AGN
+$26.3M
5
ZBH icon
Zimmer Biomet
ZBH
+$25.7M

Top Sells

Rank Stock Value
1
THC icon
Tenet Healthcare
THC
+$33.8M
2
A icon
Agilent Technologies
A
+$23.9M
3
BMY icon
Bristol-Myers Squibb
BMY
+$21.7M
4
PODD icon
Insulet
PODD
+$21.7M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$19.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.75%
2 Technology 2%
3 Communication Services 1.82%
4 Industrials 1.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CSLT
26
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$16.5M 2%
1,164,257
-20,090
-2% -$326K
ARAY icon
27
Accuray
ARAY
$28M
$16.4M 1.99%
1,866,260
+390,900
+26% +$3.38M
OXFD
28
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$16.2M 1.96%
960,820
+335,951
+54% +$6.05M
CSII
29
DELISTED
Cardiovascular Systems, Inc.
CSII
$15.4M 1.86%
493,345
+101,718
+26% +$2.93M
MODN
30
DELISTED
MODEL N, INC.
MODN
$15M 1.82%
1,360,878
+506,500
+59% +$5.18M
HMSY
31
DELISTED
HMS Holdings Corp.
HMSY
$11.5M 1.4%
+565,593
New +$10.2M
LAB icon
32
Standard BioTools
LAB
$339M
$11.5M 1.4%
+392,540
New +$12.6M
OFIX icon
33
Orthofix Medical
OFIX
$441M
$10.2M 1.23%
+280,642
New +$9.07M
INGN icon
34
Inogen
INGN
$174M
$10.2M 1.23%
450,500
-10,423
-2% -$173K
ALGN icon
35
Align Technology
ALGN
$12B
$9.83M 1.19%
175,452
-119,160
-40% -$6.2M
AKAO
36
DELISTED
Achaogen Inc
AKAO
$9.06M 1.1%
648,879
-4,821
-0.7% -$67.5K
PRTA icon
37
Prothena Corp
PRTA
$447M
$8.36M 1.01%
370,520
-189,091
-34% -$4.73M
DSCI
38
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$6.94M 0.84%
600,677
+2,600
+0.4% +$26.7K
FLXN
39
DELISTED
Flexion Therapeutics, Inc.
FLXN
$6.79M 0.82%
504,083
+10,900
+2% +$149K
GERN icon
40
Geron
GERN
$930M
$6.58M 0.8%
2,170,288
-70,085
-3% -$146K
RXDX
41
DELISTED
Ignyta, Inc.
RXDX
$5.25M 0.64%
577,653
-22,347
-4% -$171K
IBB icon
42
PUT
iShares Biotechnology ETF
IBB
$9.32B
$2.06M 0.25%
+24,000
New +$1.89M
PPH icon
43
VanEck Pharmaceutical ETF
PPH
$936M
$403K 0.05%
6,500
– –
IBB icon
44
iShares Biotechnology ETF
IBB
$9.32B
$308K 0.04%
+3,600
New +$284K
ICPT
45
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$251K 0.03%
1,062
-50,051
-98% -$13.2M
BSX icon
46
Boston Scientific
BSX
$64.4B
$128K 0.02%
+10,000
New +$130K
VIRX
47
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$65K 0.01%
48
– –
TENX icon
48
Tenax Therapeutics
TENX
$390M
– –
0
– –
BBH icon
49
VanEck Biotech ETF
BBH
$396M
– –
-3,208
Closed -$292K
BMY icon
50
Bristol-Myers Squibb
BMY
$126B
– –
-418,500
Closed -$21.7M
1
2
3

Similar funds

KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Redmile Group's Q2 2014 Portfolio in Review

As of Q2 2014, Redmile Group held 69 positions worth $825M, down 1.6% from $838M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Redmile Group's Q2 2014 filing shows 13 new, 13 increased, 19 reduced and 21 closed positions. Its largest new stake was Medtronic: 589,974 shares worth $37.6M. The largest sale was Tenet Healthcare, an estimated $33.8M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 80% a quarter earlier, followed by Technology and Communication Services.

  • Redmile Group's largest Q2 2014 buy was Medtronic: 589,974 shares worth $37.6M.
  • Redmile Group added most to Allergan Inc in Q2 2014, an estimated $26.3M increase.
  • Redmile Group's biggest Q2 2014 reduction was Agilent Technologies, cutting an estimated $23.9M.
  • Redmile Group fully exited Tenet Healthcare in Q2 2014, selling an estimated $33.8M.
  • Redmile Group's ten largest holdings make up 40% of its $825M portfolio in Q2 2014.
  • Redmile Group opened 13 new positions and closed 21 in Q2 2014.
  • Redmile Group's portfolio value fell 1.6% quarter-over-quarter to $825M.

Based on Redmile Group's 13F filing for Q2 2014, filed 15 Aug 2014.